MONROVIA, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, is today announcing the EVO ICL Clinical Program which will be presented by Ophthalmic Surgeons to Ophthalmic Surgeons at its invitation only Surgical Experts Summit expected to be attended by over 250 surgeons and invited clinician guests from forty-three countries. The Experts Summit will be held in Vienna, Austria, directly ahead of the European Society of Cataract and Refractive Surgeons Meeting (ESCRS). Thirty-four surgeons will present clinical data and moderate presentations, panels and roundtable sessions on the EVO Visian ICL and Refractive Surgery topics of essential interest. The following is a representative selection from the thirty plus clinical topics to be addressed during the Experts Summit:
- Corneal Biomechanics in Refractive Surgery – What Do We Know Today?
- Corneal Screening – Judging the Patient by the Cornea
- Dry Eye Screening in Refractive Surgery – Increasing Patient Outcomes
- Retinal Detachment Risks in Presbyopic Myopic Patients: RLE vs. EVO Visian ICL
- 20 Years with Collamer in my Patient’s Eyes
- Quality of Vision with EVO Visian ICL in Myopia Below -5.0 Diopters
- Global EVO Patient Registry – Who are They and How Happy are They?
- Optimizing EVO Visian ICL Patient Flow in a High Volume Clinic
- EVO ICL as the Primary Option in a Large Clinic Setting
- A Prospective Clinical Evaluation of an EDOF ICL – Pilot Study.
Following the Experts Summit, STAAR will exhibit at the ESCRS in Vienna at the Reed Messe, Booth Number B104 from Saturday, September 22nd, through Tuesday, September 25th. STAAR will host Pre-Certification Surgeon Training Courses, Roundtables and Education Sessions including Digital Marketing and Patient Education tutorials. At this time, STAAR is expecting over forty talks at the Congress where STAAR is presented alone or in combination with other refractive surgical options. “We anticipate that our investment in the Vienna Experts Summit and ESCRS Congress will enhance our value clinically and commercially. We wish to thank in advance all the global refractive surgeon experts who are dedicated to making EVO ICL the premium and primary refractive procedure providing visual freedom for their patients,” said Caren Mason, President & Chief Executive Officer.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL,” which includes the EVO Visian ICL™ product line. More than 900,000 Visian ICLs have been implanted to date. To learn more about the ICL go to: www.discovericl.com. STAAR has approximately 400 full-time equivalent employees and markets lenses in over 75 countries. Headquartered in Monrovia, CA, the company operates manufacturing facilities in Aliso Viejo, CA, and Monrovia, CA. For more information, please visit the Company’s website at www.staar.com.